Celon Pharma (CLN) Q1 2026 earnings summary

Executive summary

• Total revenue for Q1 2026 reached PLN 61.9 million, a 25% increase year-over-year, driven by growth in both generic and innovative segments.

• Net profit was PLN 162.6 million, reversing a PLN 25.1 million loss a year earlier, primarily due to a one-off fair value remeasurement of the Novohale stake after ceasing equity method accounting.

• Operating profitability improved, with EBITDA turning positive at PLN 5.2 million versus a loss of PLN 5.5 million a year earlier, and EBIT loss narrowed to PLN 6.0 million from PLN 18.8 million.

• Generic segment remains profitable and funds innovative R&D, which benefited from grants and service revenues.

Financial highlights

• Generic medicines segment revenue was PLN 53.5 million, up from PLN 49.0 million year-over-year.

• Innovative segment revenue rose sharply to PLN 8.4 million from PLN 0.4 million, driven by grants and R&D services.

• Gross profit reached PLN 160.3 million, compared to a loss of PLN 22.5 million in Q1 2025.

• EBITDA margin improved to 8.3% from -11.2% year-over-year.

• Net cash from operations was PLN -11.0 million, compared to PLN -3.5 million year-over-year.

Outlook and guidance

• Phase 3 clinical trials for key innovative projects are planned for the second half of 2026, with ongoing partnership and licensing discussions.

• Management expects continued growth in both generic and innovative segments, supported by new product launches and ongoing R&D partnerships.

• Key drivers include export growth of Salmex, commercialization of innovative drugs, and further grant funding.

• Continued focus on R&D, supported by significant public grant funding exceeding PLN 254 million.

• No formal financial guidance for 2026 was published.